Education
About Us
Working with TipRanks
Follow Us
Myriad Genetics (MYGN)
NASDAQ:MYGN
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.01Same Quarter Last Year
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 24, 2025
|% Change Since: -35.56%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Neutral
Myriad Genetics reported a strong financial performance with significant revenue growth and strategic partnerships, despite facing challenges in GeneSight reimbursement and slower volume growth in certain segments.Company Guidance
During the Myriad Genetics Fourth Quarter 2024 Financial Earnings Conference Call, CEO Paul Diaz highlighted the company's 11% revenue growth in 2024 compared to 2023, with a focus on profitable growth and innovation in advanced diagnostics. Key metrics included $589 million in adjusted gross profits, $40 million in adjusted EBITDA, and a positive adjusted EPS of $0.14. The company maintained approximately $158 million in liquidity. Diaz emphasized Myriad's strong Net Promoter Score of 72, reflecting positive interactions with external groups. He also mentioned the company's strategic initiatives, including an exclusive partnership with PATHOMIQ to enhance oncology products with AI technology, and achieving 3% ASP growth. Looking ahead, Myriad aims for double-digit revenue growth, supported by new product launches and strategic partnerships to accelerate growth in 2026 and beyond.Record Revenue Growth
Myriad Genetics reported an 11% revenue growth in 2024 compared to 2023, driven by volume and revenue per test improvements across the portfolio.
Exclusive Partnership with PATHOMIQ
Myriad Genetics announced an exclusive partnership with PATHOMIQ to apply their advanced AI technology to Myriad's oncology products. This collaboration enhances Myriad's offerings in prostate cancer care.
Strong Growth in Key Segments
The GeneSight product showed a 23% revenue increase year-over-year, while hereditary cancer testing and prenatal revenue increased by 11% and 17%, respectively.
Positive Financial Performance
The company achieved $589 million in adjusted gross profits, $40 million of adjusted EBITDA, and positive adjusted EPS of $0.14 for 2024.
Strong Liquidity Position
Myriad Genetics maintained approximately $158 million in liquidity at the end of 2024.
---
MYGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MYGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 24, 2025 | $13.78 | $11.74 | -14.80% |
| Nov 07, 2024 | $17.67 | $17.41 | -1.47% |
| Aug 06, 2024 | $25.96 | $26.64 | +2.62% |
| May 07, 2024 | $19.78 | $23.95 | +21.08% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Myriad Genetics (MYGN) report earnings?
Myriad Genetics (MYGN) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Myriad Genetics (MYGN) earnings time?
Myriad Genetics (MYGN) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MYGN EPS forecast?
MYGN EPS forecast for the fiscal quarter 2025 (Q1) is -0.06.
---